Rapid and Consistent Improvements in Morning PEF in Patients with Severe Eosinophilic Asthma Treated with Mepolizumab
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Rapid and Consistent Improvements in Morning PEF in Patients with Severe Eosinophilic Asthma Treated with Mepolizumab
Authors
Keywords
AM PEF, Anti-IL-5, Blood eosinophils, Lung function, Monoclonal antibody, Respiratory, Severe asthma
Journal
ADVANCES IN THERAPY
Volume 35, Issue 7, Pages 1059-1068
Publisher
Springer Nature
Online
2018-06-15
DOI
10.1007/s12325-018-0727-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Benralizumab Treatment Produces Rapid Changes in Morning Peak Expiratory Flow in Patients With Severe, Uncontrolled Eosinophilic Asthma
- (2018) Geoffrey Chupp et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial
- (2017) Geoffrey L Chupp et al. Lancet Respiratory Medicine
- Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
- (2016) Eugene R Bleecker et al. LANCET
- Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
- (2016) J Mark FitzGerald et al. LANCET
- Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies
- (2016) Hector G Ortega et al. Lancet Respiratory Medicine
- Efficacy and Safety of Anti-Interleukin-5 Therapy in Patients with Asthma: A Systematic Review and Meta-Analysis
- (2016) Fa-Ping Wang et al. PLoS One
- Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials
- (2015) Mario Castro et al. Lancet Respiratory Medicine
- Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
- (2014) Elisabeth H. Bel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
- (2014) Hector G. Ortega et al. NEW ENGLAND JOURNAL OF MEDICINE
- International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
- (2013) K. F. Chung et al. EUROPEAN RESPIRATORY JOURNAL
- Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease
- (2013) Peter J. Barnes JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Targeting eosinophils in allergy, inflammation and beyond
- (2013) Patricia C. Fulkerson et al. NATURE REVIEWS DRUG DISCOVERY
- Asthma outcomes: Pulmonary physiology
- (2012) Robert S. Tepper et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
- (2012) Ian D Pavord et al. LANCET
- Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
- (2009) Pranabashis Haldar et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia
- (2009) Parameswaran Nair et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started